What to Expect from Altimmune's Earnings
Altimmune (NASDAQ:ALT) is preparing to release its quarterly earnings on Thursday, 2026-03-05. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Altimmune to report an earnings per share (EPS) of $-0.25.
Altimmune bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Overview of Past Earnings
During the last quarter, the company reported an EPS beat by $0.07, leading to a 4.31% increase in the share price on the subsequent day.
Here's a look at Altimmune's past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.28 | -0.32 | -0.35 | -0.34 |
| EPS Actual | -0.21 | -0.27 | -0.26 | -0.33 |
| Price Change % | 4.31 | 3.31 | -1.04 | 3.58 |
Stock Performance
Shares of Altimmune were trading at $4.16 as of March 03. Over the last 52-week period, shares are down 24.15%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
All You Need to Know About Altimmune
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Altimmune's Economic Impact: An Analysis
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Decline in Revenue: Over the 3 months period, Altimmune faced challenges, resulting in a decline of approximately 0.0% in revenue growth as of 30 September, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -380280.0%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -10.96%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Altimmune's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -9.3%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Altimmune's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
To track all earnings releases for Altimmune visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.